Harrow Health (NASDAQ:HROW) Rating Increased to Buy at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Harrow Health (NASDAQ:HROW) from a hold rating to a buy rating in a report issued on Monday morning, ValuEngine reports.

A number of other research firms have also recently issued reports on HROW. Zacks Investment Research raised Harrow Health from a sell rating to a buy rating and set a $6.00 price objective for the company in a research report on Friday, March 15th. TheStreet raised Harrow Health from a d- rating to a c rating in a research report on Wednesday, May 1st.

Shares of NASDAQ HROW opened at $7.72 on Monday. The company’s 50 day moving average is $6.03. Harrow Health has a 52 week low of $1.99 and a 52 week high of $8.05. The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $187.01 million, a PE ratio of 12.66 and a beta of -0.28.

Harrow Health (NASDAQ:HROW) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.14). Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The business had revenue of $12.29 million during the quarter, compared to analyst estimates of $12.10 million. As a group, sell-side analysts forecast that Harrow Health will post -0.1 earnings per share for the current fiscal year.

In other news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.57, for a total value of $45,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $151,200. Insiders own 12.43% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Birchview Capital LP acquired a new stake in Harrow Health in the first quarter valued at approximately $896,000. FineMark National Bank & Trust acquired a new stake in Harrow Health in the first quarter valued at approximately $113,000. Acadian Asset Management LLC acquired a new stake in Harrow Health in the first quarter valued at approximately $1,983,000. Alambic Investment Management L.P. acquired a new stake in Harrow Health in the first quarter valued at approximately $252,000. Finally, EAM Global Investors LLC acquired a new stake in Harrow Health in the first quarter valued at approximately $171,000. 32.14% of the stock is owned by institutional investors.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Read More: Trade War

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

KeyCorp Initiates Coverage on AppFolio
KeyCorp Initiates Coverage on AppFolio
Wolfgang Helmut Leoni Buys 410 Shares of Central and Eastern Europe Fund Inc  Stock
Wolfgang Helmut Leoni Buys 410 Shares of Central and Eastern Europe Fund Inc Stock
Raymond James Raises Amedisys  Price Target to $144.00
Raymond James Raises Amedisys Price Target to $144.00
Omeros’  Neutral Rating Reaffirmed at Wedbush
Omeros’ Neutral Rating Reaffirmed at Wedbush
Jefferies Financial Group Begins Coverage on Akero Therapeutics
Jefferies Financial Group Begins Coverage on Akero Therapeutics
Canaccord Genuity Begins Coverage on Slack
Canaccord Genuity Begins Coverage on Slack


 
© 2006-2019 Zolmax.